Precision Medicine Pillar No. 2: Basic Discovery. The long path to developing potent new treatments often starts with an observation in the lab that then leads to a question about a fundamental life process.
November 15, 2013
November 14, 2013
In a bold demonstration of support for children fighting cancer, UCSF Benioff Children’s Hospital will host a St. Baldrick’s Foundation signature head-shaving event where several doctors will go bald to raise money and awareness for childhood cancer research.
October 16, 2013
A UCSF-led team of scientists has discovered that a gene mutation found in some bladder cancers is indicative of low-risk tumors that are unlikely to recur or progress after surgery.
October 11, 2013
The way cells divide to form new cells – to support growth, to repair damaged tissues, or simply to maintain our healthy adult functioning – is controlled in previously unsuspected ways, UCSF researchers have discovered.
September 19, 2013
UCSF will receive a five year, $20 million grant as part of a first-of-its-kind tobacco science regulatory program by the U.S. Food and Drug Administration and the National Institutes of Health.
August 26, 2013
A team led by UCSF researchers has called for simplified guidelines on when to biopsy thyroid nodules for cancer, which they say would result in fewer unnecessary biopsies.
August 19, 2013
A natural form of sugar could offer a noninvasive way to precisely image tumors and determine whether cancer medication is effective using new technology developed at UCSF in collaboration with GE Healthcare.
July 29, 2013
A group of scientists convened by the National Cancer Institute and chaired by a UCSF breast cancer expert is proposing a major update of the way the nation approaches diseases now classified as “cancer.”
July 19, 2013
Stem-cell researchers at UCSF have found a key role for a protein called BMI1 that may help scientists direct the development of tissues to replace damaged organs in the human body.
July 18, 2013
UCSF researchers have found a way to knock down cancers caused by a tumor-driving protein called “myc,” paving the way for patients with myc-driven cancers to enroll in clinical trials for experimental treatments.